Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of SYS6090 injection combination therapy in hepatocellular carcinoma
CTR20262952Phase 2Active
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in hepatocellular carcinoma (HCC), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Started Sep 2026; status: active.
02
Drugs
toripalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20262952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262952.